Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10540887 | 0.83 | TSHR (0.47) | TSHRKMT2ALMNAMEN1MMP2 | |
| SCHEMBL19923468 | 0.78 | LMNA (0.41) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL17794055 | 0.78 | LMNA (0.62) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL19923704 | 0.78 | LMNA (0.45) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL17641492 | 0.77 | LMNA (0.40) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL19923526 | 0.77 | LMNA (0.44) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL19923426 | 0.75 | LMNA (0.40) | TSHRKMT2ALMNARECQLMEN1 | |
| SCHEMBL64294 | 0.75 | KMT2A (0.48) | TSHRKMT2ALMNAMEN1BRD4 | |
| SCHEMBL16109569 | 0.71 | MEN1 (0.43) | KMT2ALMNAMEN1MMP2BRD4 | |
| SCHEMBL11658080 | 0.71 | ATM (0.44) | KMT2AMEN1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| US-8003649-B2 | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | ASTRAZENECA AB (SE) | 2011-08-23 | — | — | US | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
| EP-2235010-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7601748-B2 | Anti-androgenic N-[ omega -[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines; treatment of prostate cancer, benign prostate hyperplasia, androgenetic alopecia, hirsutism or acne | BAYER SCHERING PHARMA AG (DE) | 2009-10-13 | — | — | US | disclosed |
| WO-2003043983-A1 | PIPERAZINE DERIVATIVES DESTABILISING ANDROGEN RECEPTORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-30 | — | — | WO | disclosed |
| WO-2001058855-A9 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA INC (US) | 2002-10-31 | — | — | WO | disclosed |
| US-6472415-B1 | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes | BIOPHYSICA, INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1169301-A1 | A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS | BIOPHYSICA, INC. (US) | 2002-01-09 | — | — | EP | disclosed |
| EP-1144366-A2 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001058855-A1 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001058854-A1 | A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS | BIOPHYSICA, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6184249-B1 | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes | BIOPHYSICA, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2000037430-A2 | USE OF ANDROGEN RECEPTOR SUPPRESSORS | BIOPHYSICA, INC. (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | TSHR 2689/4885KMT2A 828/4885LMNA 3113/4885 |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | TSHR 4786/4885KMT2A 1080/4885LMNA 336/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | TSHR 4794/4885KMT2A 999/4885LMNA 455/4885 |
| US-20100016279-A1 | BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155 | AR, NR5A1, CYP17A1 | TSHR 479/4885KMT2A 3283/4885LMNA 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.